These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1 Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236 [TBL] [Abstract][Full Text] [Related]
7. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. Zhang X; Niedermann G Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901 [TBL] [Abstract][Full Text] [Related]
8. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467 [TBL] [Abstract][Full Text] [Related]
9. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174 [No Abstract] [Full Text] [Related]
10. PD-1 Status in CD8 Kansy BA; Concha-Benavente F; Srivastava RM; Jie HB; Shayan G; Lei Y; Moskovitz J; Moy J; Li J; Brandau S; Lang S; Schmitt NC; Freeman GJ; Gooding WE; Clump DA; Ferris RL Cancer Res; 2017 Nov; 77(22):6353-6364. PubMed ID: 28904066 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. Lu Y; Houson HA; Gallegos CA; Mascioni A; Jia F; Aivazian A; Song PN; Lynch SE; Napier TS; Mansur A; Larimer BM; Lapi SE; Hanker AB; Sorace AG Breast Cancer Res; 2024 Jun; 26(1):104. PubMed ID: 38918836 [TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models. Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066 [TBL] [Abstract][Full Text] [Related]
14. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602 [TBL] [Abstract][Full Text] [Related]
15. The PET-Tracer Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308 [TBL] [Abstract][Full Text] [Related]
16. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Rashidian M; LaFleur MW; Verschoor VL; Dongre A; Zhang Y; Nguyen TH; Kolifrath S; Aref AR; Lau CJ; Paweletz CP; Bu X; Freeman GJ; Barrasa MI; Weinberg RA; Sharpe AH; Ploegh HL Proc Natl Acad Sci U S A; 2019 Aug; 116(34):16971-16980. PubMed ID: 31375632 [TBL] [Abstract][Full Text] [Related]
17. Immuno-PET Monitoring of CD8 Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600 [TBL] [Abstract][Full Text] [Related]
18. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
19. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. Fransen MF; Schoonderwoerd M; Knopf P; Camps MG; Hawinkels LJ; Kneilling M; van Hall T; Ossendorp F JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518694 [TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]